41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
T lymphocytes
cell engineering
immunotherapy, adoptive
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
accepted:
07
05
2020
entrez:
13
6
2020
pubmed:
13
6
2020
medline:
21
8
2021
Statut:
ppublish
Résumé
Acute myeloid leukemia (AML) is a hematopoietic malignancy which is biologically, phenotypically and genetically very heterogeneous. Outcome of patients with AML remains dismal, highlighting the need for improved, less toxic therapies. Chimeric antigen receptor T-cell (CART) immunotherapies for patients with refractory or relapse (R/R) AML are challenging because of the absence of a universal pan-AML target antigen and the shared expression of target antigens with normal hematopoietic stem/progenitor cells (HSPCs), which may lead to life-threating on-target/off-tumor cytotoxicity. CD33-redirected and CD123-redirected CARTs for AML are in advanced preclinical and clinical development, and they exhibit robust antileukemic activity. However, preclinical and clinical controversy exists on whether such CARTs are myeloablative. We set out to comparatively characterize in vitro and in vivo the efficacy and safety of 41BB-based and CD28-based CARCD123. We analyzed 97 diagnostic and relapse AML primary samples to investigate whether CD123 is a suitable immunotherapeutic target, and we used several xenograft models and in vitro assays to assess the myeloablative potential of our second-generation CD123 CARTs. Here, we show that CD123 represents a bona fide target for AML and show that both 41BB-based and CD28-based CD123 CARTs are very efficient in eliminating both AML cell lines and primary cells in vitro and in vivo. However, both 41BB-based and CD28-based CD123 CARTs ablate normal human hematopoiesis and prevent the establishment of de novo hematopoietic reconstitution by targeting both immature and myeloid HSPCs. This study calls for caution when clinically implementing CD123 CARTs, encouraging its preferential use as a bridge to allo-HSCT in patients with R/R AML.
Sections du résumé
BACKGROUND
Acute myeloid leukemia (AML) is a hematopoietic malignancy which is biologically, phenotypically and genetically very heterogeneous. Outcome of patients with AML remains dismal, highlighting the need for improved, less toxic therapies. Chimeric antigen receptor T-cell (CART) immunotherapies for patients with refractory or relapse (R/R) AML are challenging because of the absence of a universal pan-AML target antigen and the shared expression of target antigens with normal hematopoietic stem/progenitor cells (HSPCs), which may lead to life-threating on-target/off-tumor cytotoxicity. CD33-redirected and CD123-redirected CARTs for AML are in advanced preclinical and clinical development, and they exhibit robust antileukemic activity. However, preclinical and clinical controversy exists on whether such CARTs are myeloablative.
METHODS
We set out to comparatively characterize in vitro and in vivo the efficacy and safety of 41BB-based and CD28-based CARCD123. We analyzed 97 diagnostic and relapse AML primary samples to investigate whether CD123 is a suitable immunotherapeutic target, and we used several xenograft models and in vitro assays to assess the myeloablative potential of our second-generation CD123 CARTs.
RESULTS
Here, we show that CD123 represents a bona fide target for AML and show that both 41BB-based and CD28-based CD123 CARTs are very efficient in eliminating both AML cell lines and primary cells in vitro and in vivo. However, both 41BB-based and CD28-based CD123 CARTs ablate normal human hematopoiesis and prevent the establishment of de novo hematopoietic reconstitution by targeting both immature and myeloid HSPCs.
CONCLUSIONS
This study calls for caution when clinically implementing CD123 CARTs, encouraging its preferential use as a bridge to allo-HSCT in patients with R/R AML.
Identifiants
pubmed: 32527933
pii: jitc-2020-000845
doi: 10.1136/jitc-2020-000845
pmc: PMC7292050
pii:
doi:
Substances chimiques
CD28 Antigens
0
Interleukin-3 Receptor alpha Subunit
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Curr Treat Options Oncol. 2017 Mar;18(3):17
pubmed: 28286924
Cell. 2018 May 31;173(6):1439-1453.e19
pubmed: 29856956
Leukemia. 2020 Dec;34(12):3228-3241
pubmed: 32111969
Bone Marrow Res. 2012;2012:406796
pubmed: 22852088
Nat Med. 1997 Jul;3(7):730-7
pubmed: 9212098
Clin Cancer Res. 2015 Sep 1;21(17):3977-85
pubmed: 25957287
Cell Stem Cell. 2018 Feb 1;22(2):157-170
pubmed: 29395053
Blood. 2019 May 23;133(21):2291-2304
pubmed: 30796021
Genes (Basel). 2020 Jan 09;11(1):
pubmed: 31936647
Br J Haematol. 2009 Feb;144(3):376-87
pubmed: 19036083
Blood. 2001 Oct 15;98(8):2301-7
pubmed: 11588023
Blood. 2014 Feb 20;123(8):1218-28
pubmed: 24363400
Cytometry B Clin Cytom. 2019 Mar;96(2):134-142
pubmed: 30450744
Blood. 2011 Jul 28;118(4):992-1001
pubmed: 21633088
Br J Haematol. 2013 May;161(3):389-401
pubmed: 23432359
Leuk Lymphoma. 2003 Mar;44(3):391-409
pubmed: 12688309
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
Oncoscience. 2018 Feb 23;5(1-2):9-10
pubmed: 29556512
J Exp Med. 2009 Dec 21;206(13):3131-41
pubmed: 19995953
Nat Commun. 2016 Aug 22;7:12484
pubmed: 27546487
Curr Opin Genet Dev. 2016 Feb;36:100-6
pubmed: 27162099
Int J Mol Sci. 2019 Jun 11;20(11):
pubmed: 31212634
Blood. 2011 Nov 3;118(18):4817-28
pubmed: 21849486
Haematologica. 2015 Jul;100(7):914-26
pubmed: 26130514
Blood. 2015 Jan 29;125(5):767-74
pubmed: 25515963
Blood. 2014 Apr 10;123(15):2343-54
pubmed: 24596416
Blood. 2012 Oct 18;120(16):3187-205
pubmed: 22879540
Blood. 2017 Jul 20;130(3):285-296
pubmed: 28539325
Ther Adv Hematol. 2018 Jun;9(6):135-148
pubmed: 29899889
Blood. 2015 Jul 16;126(3):319-27
pubmed: 25852056
Blood. 2013 Oct 31;122(18):3138-48
pubmed: 24030378
Blood Adv. 2017 Jun 20;1(15):1067-1079
pubmed: 29296749
Exp Hematol. 2019 Jun;74:52-63.e3
pubmed: 31136781
Blood. 2017 Apr 27;129(17):2395-2407
pubmed: 28246194
Int J Hematol. 2019 May;109(5):539-544
pubmed: 30847774
Haematologica. 2020 Feb 06;105(12):2855-2860
pubmed: 33256387
J Immunother Cancer. 2018 Nov 5;6(1):116
pubmed: 30396365
Leukemia. 2004 Feb;18(2):219-26
pubmed: 14671644
Leukemia. 2014 Aug;28(8):1596-605
pubmed: 24504024
Blood. 2015 Aug 20;126(8):983-92
pubmed: 26056165
Oncotarget. 2018 Sep 25;9(75):34056-34065
pubmed: 30344921
Haematologica. 2014 Jul;99(7):1168-75
pubmed: 24727813
Cancer. 2013 Aug 1;119(15):2720-7
pubmed: 23633441
Blood. 2016 Jan 7;127(1):122-31
pubmed: 26531164
Blood. 2016 Jan 7;127(1):62-70
pubmed: 26660427
Blood. 2010 Nov 18;116(20):4099-102
pubmed: 20668228
J Hematol Oncol. 2016 Jul 27;9(1):61
pubmed: 27465508
Cancers (Basel). 2019 Sep 12;11(9):
pubmed: 31547472
Stem Cells. 2013 Oct;31(10):2061-72
pubmed: 23836491
Leuk Lymphoma. 2015 May;56(5):1406-15
pubmed: 25248882
Leukemia. 2015 Aug;29(8):1637-47
pubmed: 25721896
Ann Transl Med. 2017 Feb;5(4):80
pubmed: 28275625
Lancet Oncol. 2014 Aug;15(9):986-96
pubmed: 25008258
JCI Insight. 2018 Jan 11;3(1):
pubmed: 29321369